Modality
Bispecific Ab
MOA
CD47i
Target
Aβ
Pathway
PI3K/AKT
UC
Development Pipeline
Preclinical
Feb 2023
→ Jul 2028
PreclinicalCurrent
NCT06290271
806 pts·UC
2025-01→2028-07·Terminated
NCT04590984
337 pts·UC
2023-02→2026-07·Terminated
1,143 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-214mo awayInterim· UC
2028-07-122.3y awayInterim· UC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Termina…
Preclinical
Termina…
Catalysts
Interim
2026-07-21 · 4mo away
UC
Interim
2028-07-12 · 2.3y away
UC
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06290271 | Preclinical | UC | Terminated | 806 | HAM-D |
| NCT04590984 | Preclinical | UC | Terminated | 337 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Zenonesiran | GSK | Preclinical | DLL3 |